ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer : vimarsana.com

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer

QUILT 3.055 trial completed and shows median overall survival almost double that of standard of care chemotherapy in 2nd- and 3rd-line non-small cell lung cancer patients whose cancer did not...

Related Keywords

United States , San Antonio , Texas , Canada , American , , American Urological Association , Exchange Commission , Immunitybio Inc , Nasdaq , American Cancer Society , Company Form , Patrick Soon Shiong , Executive Chairman , Global Chief Scientific , Medical Officer , Cancer Moonshot , Canada Toll Free , Private Securities Litigation Reform Act , Markets ,